Cure Sickle Cell

治愈镰状细胞

• 批准号: 10912972
• 负责人: MARY EAPEN
• 金额: $ 1355.78万
• 依托单位: MEDICAL COLLEGE OF WISCONSIN
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-28 至 2026-09-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10912972
• 关键词: Advocate; Caregivers; Collaborations; Communities; Family member; Government Agencies; Individual; National Heart, Lung, and Blood Institute; Patients; Research Personnel; Sickle Cell; Sickle Cell Anemia; Technology; Work; biopharmaceutical industry; gene therapy; improved; innovation; public-private partnership

The Cure Sickle Cell (CureSC) Initiative was created in 2017 by the National Heart, Lung, and Blood Institute (NIH/NHLBI) to: • Actively engage the sickle cell disease community of patients, family members, caregivers and advocates to work together on a path to the cure • Utilize the emergence of safe reliable genetic therapies that broadens opportunities to improve the lives of individuals with sickle cell disease • Use public-private partnership and collaboration among government agencies, biopharmaceutical companies and researchers to result in more rapid advancement of new and innovative treatments and technologies

治愈镰状细胞 (CureSC) 计划由国家心肺血液研究所 (NIH/NHLBI) 于 2017 年创建，旨在： • 积极参与镰状细胞病患者、家庭成员、护理人员和倡导者社区的参与，共同致力于治愈疾病的道路 • 利用安全可靠的基因疗法的出现，拓宽改善镰状细胞病患者生活的机会 • 利用政府机构、生物制药公司和研究人员之间的公私伙伴关系和协作，更快地推进新的创新疗法和技术